3 terminated, 2 completed, 1 unknown, 1 withdrawn. 5 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Terminated 3, Unknown 1, Withdrawn 1 |
| Phase 2 | 2 | Completed 2 |
Follow Bellerophon Pulse Technologies: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis at Risk for Pulmonary Hypertension INOpulse®, Placebo, Open Label Extension - Pulmonary Fibrosis, Pulmonary Hypertension | Phase 3 | Terminated | Bellerophon Pulse Technologies | 145 | 2020-12-14 | 2023-07-27 |
| A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19 INOpulse, Placebo - COVID-19, Coronavirus | Phase 3 | Terminated | Bellerophon Pulse Technologies | 191 | 2020-07-12 | 2023-02-21 |
| Study of PAH Subjects With LTOT Use That Have Demonstrated Improved Exercise Tolerance With the Use of Inhaled Nitric Placebo, iNO - Pulmonary Arterial Hypertension | Phase 3 | Withdrawn | Bellerophon Pulse Technologies | 2018-08-01 | 2023-02-21 | |
| Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH Inhaled Nitric Oxide 75 mcg/kg IBW/hr, Placebo - Pulmonary Arterial Hypertension | Phase 3 | Terminated | Bellerophon Pulse Technologies | 207 | 2016-04-01 | 2023-02-21 |
| Long-Term Extension Study of Inhaled Nitric Oxide (iNO) for PAH Inhaled Nitric Oxide - Pulmonary Arterial Hypertension | Phase 3 | Unknown | Bellerophon Pulse Technologies | 22 | 2016-03-01 | 2023-02-21 |
| Two-Part Dose-Confirming Study of Pulsed Inhaled Nitric Oxide in Subjects With WHO Group 3 Pulmonary Hypertension Associated With COPD Inhaled NO delivered via INOpulse DS-C Device, Placebo delivered via INOpulse DS-C Device - Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease | Phase 2 | Completed | Bellerophon Pulse Technologies | 159 | 2012-12-01 | 2023-02-27 |
| Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH) Inhaled Nitric Oxide 0.025 mg/kg IBW/hr delivered via INOpulse DS Device, Placebo delivered via INOpulse DS Device, Inhaled nitric oxide 0.075 mg/kg IBW/hr delivered via INOpulse DS Device - Pulmonary Arterial Hypertension, Pulmonary Hypertension | Phase 2 | Completed | Bellerophon Pulse Technologies | 80 | 2012-04-01 | 2023-02-27 |
Pulmonary Arterial Hypertension (4) · Hypertension, Pulmonary (3) · COVID-19 (1) · Coronavirus Infections (1) · Pneumonia (1) · Pulmonary Disease, Chronic Obstructive (1) · Pulmonary Fibrosis (1) · Severe Acute Respiratory Syndrome (1)
Nitrogen (1)
United States (7) · Canada (5) · Australia (1) · Austria (1) · Belgium (1) · Colombia (1) · Croatia (1) · Czechia (1) · France (1) · Germany (1) · Israel (1) · Italy (1) · Netherlands (1) · Portugal (1) · Serbia (1)
Ashika Ahmed, MD (6) · Ashika Ahmed (1)